Before starting retatrutide whether in a trial or, in future, as a licensed medicine the following topics should be discussed with your doctor: Your full medical history , including any personal or family history of thyroid cancer, pancreatitis, gallbladder disease, cardiovascular conditions, diabetic retinopathy, or gastrointestinal disorders such as gastroparesis Current medications : Retatrutide may interact with insulin or other antidiabetic agents, potentially increasing the risk of hypoglycaemia
All products from The Peptide Co are sold for research purposes only
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al
Those situations are framed as needing clinical judgment rather than a general safety statement
The starting dosage is 0.8 milligrams (mg), increased to 2.5 mg after at least 30 days, and then to 5.5 mg after another 30 days